Also on rt.com
The Russian partner also pledged to supply data from the clinical trial of Sputnik V conducted in Russia, saying it will help “further strengthen the clinical development” of the vaccine in India.
Russia registered the new vaccine in August, before a large-scale Phase-3 clinical trial was conducted. The developer managed to convince the Russian drug licensing agency that its product, which is based on a time-tested platform, was safe to use. A proper efficacy study, involving 40,000 volunteers, is currently coming to an end in the country.
The novel drug was also supplied to several other countries, including Belarus, Venezuela and the UAE, where separate Phase-3 trials of the Russian vaccine are underway.
If you like this story, share it with a friend!